ALK-rearranged squamous cell lung cancer: a case report

被引：1

作者：

Zhang, Quan ^{[1
]}

Wang, Jinghui ^{[1
]}

Zhang, Shucai ^{[1
]}

机构：

[1] Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Med Oncol, Beijing, Peoples R China

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2015年 / 8卷 / 02期

关键词：

ALK rearrangement; squamous cell carcinoma; crizotinib; FUSION GENE; CRIZOTINIB; CARCINOMA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ALK rearrangement is a very rare subset of squamous cell cancer of lung and the efficacy of crizotinib treatment for these patients is lack of data. Here we report a case with squamous cell cancer of lung that harbored the ALK rearrangement was given crizotinib in the second-line therapy. A 55-year-old female patient was diagnosed with squamous cell carcinoma of lung by bronchoscopy biopsy with stage IV. The patient was given two cycles of chemotherapy and the response was progressive disease. After failure to chemotherapy, genotype testing showed wild-type EGFR/KRAS and ALK rearrangement positive. The patient was administered with crizotinib and had a partial response, and the progression-free survival was 6 months. The side effects were tolerable.

引用

页码：2195 / 2198

页数：4

共 50 条

[1] ALK-rearranged squamous cell carcinoma of the lung
Takanashi, Yusuke
Tajima, Shogo
Matsuura, Shun
Koyama, Shin
Takahashi, Tsuyoshi
Neyatani, Hiroshi
[J]. RESPIROLOGY CASE REPORTS, 2015, 3 (03): : 105 - 107
[2] ALK-rearranged squamous cell carcinoma of the lung
Meng, Qiyi
Dong, Yujie
Tao, Hong
Shi, Liang
Tong, Li
Tang, Junfang
Zhang, Shucai
Liu, Zhe
[J]. THORACIC CANCER, 2021, 12 (07) : 1106 - 1114
[3] ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
Mamesaya, Nobuaki
Nakashima, Kazuhisa
Naito, Tateaki
Nakajima, Takashi
Endo, Masahiro
Takahashi, Toshiaki
[J]. BMC CANCER, 2017, 17
[4] ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
Nobuaki Mamesaya
Kazuhisa Nakashima
Tateaki Naito
Takashi Nakajima
Masahiro Endo
Toshiaki Takahashi
[J]. BMC Cancer, 17
[5] Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer
Shiihara, Jun
Ohyanagi, Fumiyoshi
Amari, Hikari
Toda, Minemichi
Tahara, Hiroki
Yuzawa, Motoi
Maeda, Yuki
Nomura, Motoko
Mizushina, Yoshiko
Nagai, Yoshiaki
Ohta, Hiromitsu
Yamaguchi, Yasuhiro
[J]. THORACIC CANCER, 2021, 12 (17) : 2420 - 2423
[6] Lorlatinib in ALK-Rearranged Lung Cancer
Kuang, Shelley
Leighl, Natasha B.
[J]. CANCER CELL, 2021, 39 (01) : 25 - 27
[7] ALK-Rearranged Lung Cancer Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma
Chaft, Jamie E.
Rekhtman, Natasha
Ladanyi, Marc
Riely, Gregory J.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (04) : 768 - 769
[8] First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report
Scarfone, Giovanna
Fumagalli, Monica
Imbimbo, Martina
Ceruti, Tommaso
Cribiu, Fulvia Milena
Di Loreto, Eugenia
D'Incalci, Maurizio
Facchin, Federica
Fontana, Camilla
Garassino, Marina C.
Peccatori, Fedro A.
Persico, Nicola
Signorelli, Diego
Zucchetti, Massimo
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 873 - 877
[9] ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report
Chen, Rui
Jian, Yan
Liu, Yuzhen
Xie, Junping
[J]. FRONTIERS IN ONCOLOGY, 2024, 14
[10] Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report
Yao, Bin
Han, Xue
Pang, Linrong
Xu, Caihong
Liu, Sisi
Cheng, Xiaochun
Chen, Jun
[J]. ONCOTARGETS AND THERAPY, 2021, 14 : 4329 - 4333

← 1 2 3 4 5 →